Recombinant Humanized monoclonal antibody expressed in CHO binding to Human WNVE Protein. MGAWN1 is an investigational anti-WNV humanized monoclonal antibody being developed for the treatment of West Nile virus infections. The results of this Phase 1 study suggest that single infusions of MGAWN1 up to 30 mg/kg appear to be safe and well tolerated in healthy subjects.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for TAB-669CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.